COVID-19 Vaccination in Adolescents: Side Effects and Symptomatic Reinfections

被引:0
作者
Mazaheri, Maryam [1 ]
Moazen, Javad [2 ]
Rezaei, Zahed [3 ]
Aghababaeian, Hamidreza [4 ,5 ]
Mohebbi, Leila [6 ]
Eghtedari, Mohammad Amin [7 ]
Nikjoo, Mohammad [7 ]
Shoush, Ali [7 ]
Hedayat, Zahra [8 ]
机构
[1] Dezful Univ Med Sci DUMS, Sch Med, Dept Social Med & Family, Dezful, Iran
[2] Dezful Univ Med Sci DUMS, Infect & Trop Dis Res Ctr, Sch Med, Dezful, Iran
[3] Asadabad Sch Med Sci, Asadabad 6541743897, Iran
[4] Dezful Univ Med Sci DUMS, Dept Med Emergencies, Dezful, Iran
[5] Dezful Univ Med Sci DUMS, Ctr Climate Change & Hlth Res CCCHR, Dezful, Iran
[6] Dezful Univ Med Sci DUMS, Dept Hlth, Dezful, Iran
[7] Dezful Univ Med Sci DUMS, Sch Med, Dezful, Iran
[8] Ahvaz Jundishapur Univ Med Sci AJUMS, Student Res Comm, Ahvaz, Iran
来源
ARCHIVES OF CLINICAL INFECTIOUS DISEASES | 2023年 / 18卷 / 06期
关键词
PastoCovac Vaccine; Sinopharm Vaccine; SARS-COV-2; Reinfection; Side Effects; Symptomatic Reinfections;
D O I
10.5812/archcid-142060
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Although the COVID-19 pandemic is over, the disease remains a public health threat. Contracting and transmitting SARS-COV-2 among individuals under 18 is significant. Objectives: This study aims to identify potential side effects and symptomatic reinfections among 12 -18 -year -olds after receiving COVID-19 vaccines. Methods: In this longitudinal study conducted in 2021- 2022 in Dezful, Iran, 1,000 vaccinated individuals were followed up for 6 months. Side effects and symptomatic reinfections of the first and second doses of PastoCovac and Sinopharm vaccines and a history of prior SARS-COV-2 infection were recorded. Results: Only 7.6% received the PastoCovac vaccine, while 92.4% received the Sinopharm vaccine. The most common side effect for both vaccines was local pain at the injection site, while the least common was skin rash. Side effects were 1.9 times more prevalent with the PastoCovac vaccination. Women had a 2.3 times higher chance of experiencing side effects after the first dose and a 1.9 times higher chance after the second dose compared to men. Over the 6 -month follow-up period, 11.6% and 14.3% of individuals experienced re -infection after the first and second vaccine doses, respectively. It seems with the passage of time and the decrease in the level of immunity, the possibility of re -infection increases. Conclusions: Both vaccines were considered safe for 12 -18 -year -olds. However, receiving two doses does not guarantee protection against reinfection.
引用
收藏
页数:10
相关论文
共 44 条
  • [21] Current Prevention of COVID-19: Natural Products and Herbal Medicine
    Huang, Junqing
    Tao, Gabriel
    Liu, Jingwen
    Cai, Junming
    Huang, Zhongyu
    Chen, Jia-xu
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [22] The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues
    Khan, Naushad Ahmad
    Al-Thani, Hassan
    El-Menyar, Ayman
    [J]. TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2022, 45
  • [23] Khobragade A, 2022, LANCET, V399, P1313, DOI 10.1016/S0140-6736(22)00151-9
  • [24] COVID-19 vaccination for children aged 5-11 years
    Ladhani, Shamez
    [J]. LANCET, 2022, 400 (10346) : 74 - 76
  • [25] Mohsin M., 2022, medRxiv
  • [26] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
    Mulligan, Mark J.
    Lyke, Kirsten E.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Neuzil, Kathleen
    Raabe, Vanessa
    Bailey, Ruth
    Swanson, Kena A.
    Li, Ping
    Koury, Kenneth
    Kalina, Warren
    Cooper, David
    Fontes-Garfias, Camila
    Shi, Pei-Yong
    Tuereci, Oezlem
    Tompkins, Kristin R.
    Walsh, Edward E.
    Frenck, Robert
    Falsey, Ann R.
    Dormitzer, Philip R.
    Gruber, William C.
    Sahin, Ugur
    Jansen, Kathrin U.
    [J]. NATURE, 2020, 586 (7830) : 589 - +
  • [27] Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
    Munoz, Flor M.
    Sher, Lawrence D.
    Sabharwal, Charu
    Gurtman, Alejandra
    Xu, Xia
    Kitchin, Nicholas
    Lockhart, Stephen
    Riesenberg, Robert
    Sexter, Joanna M.
    Czajka, Hanna
    Paulsen, Grant C.
    Maldonado, Yvonne
    Walter, Emmanuel B.
    Talaat, Kawsar R.
    Englund, Janet A.
    Sarwar, Uzma N.
    Hansen, Caitlin
    Iwamoto, Martha
    Webber, Chris
    Cunliffe, Luke
    Ukkonen, Benita
    Martinez, Silvina N.
    Pahud, Barbara A.
    Munjal, Iona
    Domachowske, Joseph B.
    Swanson, Kena A.
    Ma, Hua
    Koury, Kenneth
    Mather, Susan
    Lu, Claire
    Zou, Jing
    Xie, Xuping
    Shi, Pei-Yong
    Cooper, David
    Tuereci, Oezlem
    Sahin, Ugur
    Jansen, Kathrin U.
    Gruber, William C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (07) : 621 - 634
  • [28] Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
    Nordstrom, Peter
    Ballin, Marcel
    Nordstrom, Anna
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (06) : 781 - 790
  • [29] Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study
    Omeish, Haya
    Najadat, Angam
    Al-Azzam, Sayer
    Tarabin, Nada
    Abu Hameed, Amer
    Al-Gallab, Neebal
    Abbas, Hadeel
    Rababah, Lana
    Rabadi, Majd
    Karasneh, Reema
    Aldeyab, Mamoon A.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [30] Vaccines for Covid-19: An insight on their effectiveness and adverse effects
    Qamar, Naila
    Rukh, Gul
    Khan, Sadiq N.
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (08) : 3554 - 3560